+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
E

Actively Recruiting

Researchers are studying the effects of Deucravacitinib BMS-986165 in adolescents aged 12 to 17 years with moderate to severe plaque psoriasis. The study aims to assess the drugs effectiveness, safety, and how it behaves in the body. This phase 3 trial is designed as a randomized, double-blind, placebo-controlled investigation to provide clear evidence of the drugs impact in this younger population. Participants are randomly assigned to receive either Deucravacitinib or a placebo following specified dosing schedules. The study involves a parallel group design where the treatment is given on specified days. The trial will monitor participants closely over time to evaluate treatment responses and any side effects, especially focusing on improvements in psoriasis severity and skin condition. During the study, participants will have regular assessments including measurement of psoriasis severity by Psoriasis Area and Severity Index PASI and Physicians Global Assessment sPGA, body surface area affected, itch severity, and quality of life. Safety monitoring includes checking for adverse events, laboratory tests, physical exams, vital signs, and vaccine antibody levels. The study also tracks growth and sexual maturation over up to five years, providing long-term data on drug safety and participant health.

Age: 12Years - 17YearsAll GendersPhase 3
133 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tacabrutideg compared with pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. This phase 3, open-label, randomized study focuses on patients whose disease has relapsed or not responded after at least one line of therapy including a cBTKi. Participants will be randomly assigned to receive either tacabrutideg or pirtobrutinib, both given orally. The study compares the two drugs in parallel groups to assess their safety and efficacy over the course of treatment. During the study, participants will be closely monitored for disease progression, survival, response rates, duration of response, time to next treatment, adverse events, and quality of life using standardized questionnaires. These assessments will be conducted for up to approximately 3 years to evaluate the long-term outcomes and safety profiles of the treatments.

Age: 18Years +All GendersPhase 3
217 locations
N

Actively Recruiting

Healthy Volunteer

Hyposalivation, or dry mouth, is a condition that has become more common due to factors like aging, multiple medications, chronic or autoimmune diseases, and radiation treatments, especially affecting older adults. This condition impacts saliva production, which is vital for oral health, digestion, and speech. Current treatments mainly provide temporary relief, so researchers are exploring new long-term methods to improve saliva quality and quantity and enhance patients quality of life. This research evaluates neuroelectrical stimulation TENS as a treatment for dry mouth. Patients will receive TENS therapy using self-adhesive electrodes placed near the salivary glands, with sessions lasting 30 minutes at specific electrical settings. If TENS does not increase saliva production, magnetic field therapy will be offered as an alternative. Treatments will be applied twice weekly for three weeks, with follow-ups at six months and one year, including maintenance therapy. Participants will undergo clinical exams, saliva collection, and quality of life assessments before and after treatment. Saliva will be tested for flow rate, pH, buffering capacity, and viscosity. Oral moisture and dental health will also be monitored. Questionnaires will evaluate changes in quality of life related to dry mouth. The study will analyze these measures over one year to assess the effects of the neuroelectrostimulation treatment.

Age: 12Years - 90YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating a new treatment combination for adults with advanced small cell lung cancer SCLC. The study compares a medicine called obrixtamig combined with standard treatment atezolizumab, carboplatin, and etoposide against the standard treatment alone. Obrixtamig is an antibody-like molecule designed to help the immune system fight cancer. The study also tests a new medical device to measure levels of a tumor marker called DLL3. Participants are randomly assigned to one of two groups. One group receives obrixtamig plus the standard treatment, while the other group receives only the standard treatment. All drugs are given through infusions into a vein. Participants in the obrixtamig group stay overnight at the study site after their first two obrixtamig treatments. The study lasts for up to three years, during which participants visit the study site regularly. Throughout the study, doctors monitor tumor size to compare results between groups. They also check participants overall health and note any side effects. Researchers measure outcomes such as overall survival, progression-free survival, symptom changes, treatment responses, and any treatment-related side effects. Participants are closely observed for up to 36 months to evaluate these effects and safety.

Age: 18Years +All GendersPhase 3
243 locations
A

Actively Recruiting

Researchers are evaluating the effect of adding obrixtamig, an antibody-like medicine, to standard chemotherapy carboplatin and etoposide for adults with advanced extrapulmonary neuroendocrine cancer. The study aims to see if this combination improves survival compared to chemotherapy alone. The study also tests a new medical device to measure levels of a tumor marker called delta-like ligand 3 DLL3. Participants are randomly assigned to one of two groups. One group receives obrixtamig plus standard chemotherapy infusions, followed by obrixtamig alone for up to three years. The other group receives standard chemotherapy infusions only for about four months. Treatments are given through a vein. Participants in the obrixtamig group stay overnight at the study site after the first two treatments. During the study, all participants visit the study site regularly for health checks and monitoring for side effects. Doctors measure tumor size at some visits and compare results between the two groups to evaluate treatment effects. The main measure is overall survival up to 38 months. Other assessments include progression-free survival, physical functioning, response duration, and treatment side effects. The study continues until December 2029.

Age: 18Years +All GendersPhase 3
168 locations